BioSight
Companies
HUTCHMED (China) Ltd logo

HCM

NASDAQHONG KONG
HUTCHMED (China) Ltd

HUTCHMED (China) Ltd is an oncology and immunology-focused biotech company developing small molecules and antibody-drug conjugates for indications including acute myeloid leukemia, chronic lymphocytic leukemia, diffuse large B cell lymphoma, colorectal cancer, cervical cancer, and biliary tract cancer. HUTCHMED operates through clinical-stage and commercial programs targeting pathways such as BTK, EGFR, AKT, and CSF-1R, with operations in China and internationally through multiple subsidiaries.

Price history not yet available for HCM.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar